List of Vaccines Companies in China - 28

The company develops vaccines toinduceimmunotolerance or stimulate T cells, for certain diseases. Beijing Advaccine is also collaborating with Inovio Pharmaceuticals on a novel vaccine to prevent COVID-19.

Zhifei is a high-tech biological enterprise integrating the R&D, production, distribution as well as import & export to mainly produce vaccines for human use.

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio's strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.

China National Pharmaceutical Group Corporation, SINOPHARM, is the largest pharmaceutical and healthcare group under State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) in China, with core business of pharmaceutical distribution, scientific research and manufacture of medical and biotech products. The group has 16 wholly-owned subsidiaries and holding companies, one H-share listed company, Sinopharm Group Co., Ltd., and four A-share listed companies, China National Medicines Co., Ltd. (CNCM), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and Shenzhen Accord Pharmaceutical Co., Ltd. (Accord). In 2009, the group's revenue had reached 65 billion Yuan. Among the 129 central enterprises, SINOPHARM is ranked 50th and 38th in terms of revenue and total profit respectively. In 2010, SINOPHARM's revenue is estimated to be 80 billion Yuan. SINOPHARM is the president unit of CPIA, CNNDA, CAPC, Sino-PhRDA, CAMDI, CATCM and CPCS etc., and also the sponsor and supporter of many important exhibitions including PHARMCHINA.

Established in 2012, BravoVax is located at BravoVax Building, 858 Gaoxin Avenue in the state-level biopharma development zone, Donghu hi-tech park of Wuhan, China. Relying on the experienced management team and international channels from parent company BravoBio and strong support from Humanwell Healthcare Group, one of the top 20 Chinese pharmaceuticals, we have kept the momentum in its development, maintaining fast growth. We are committed to the research and development of human vaccines and other biological products. The new pilot facility and R&D center are built at Wuhan biopharaceutical industrial park as per cGMP. All staffs hold a college and above degree, and more than 30% of them have master and above degrees as well as senior professional titles.

CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting-edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with 17 vaccines preventing 12 diseases, including approved vaccines for Ebola virus disease (Ad5-EBOV), COVID-19 (Ad5-nCoV, trade name: Convidecia), and meningitis (MCV2, trade name: Menphecia). CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates. Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology as well as formulation and delivery technology.

Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma’s innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease). Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

复旦大学，简称复旦，始建于1905年，初名复旦公学，是中国人自主创办的第一所高等学校，创始人为中国近代知名教育家马相伯，首任校董为国父孙中山先生。"复旦"二字选自《尚书大传·虞夏传》中"日月光华，旦复旦兮"的名句，意在自强不息，寄托当时中国知识分子自主办学、教育强国的希望。 复旦大学是教育部与上海市共建的首批全国重点大学，中国首批7所211工程、9所985工程大学，首批"珠峰计划"、"111计划"和中国顶尖学府"九校联盟"（C9联盟）的成员大学。

Hengsai Bio is a tumor immunotherapy developer that engages in R&D and industrialisation of a new generation dendritic cell tumor vaccines.

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Immorna is a rapidly expanding biotechnology company, focusing on the development of mRNA-based therapeutics and vaccines. Immorna is utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA. Since it’s founding in 2019, Immorna has built a robust CMC platform for mRNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of mRNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Immorna has a growing intellectual property portfolio and a diverse mRNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology and infectious disease drug candidates into their clinical stages.

The company is focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immuno Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.

Innovax delivers superior, long-term disease protection against infectious poultry diseases. Through rigorous research and development, it develops new ways to optimize flock protection and increase production efficiency with breakthrough vaccinations.

Founded in 2018, Jianda Biopharmaceuticals (Nanjing) Co., Ltd. is a biopharmaceutical company founded by domestic and foreign vaccine research and development, industrialization and commercialization experts and an elite team in the pharmaceutical industry. Its headquarters is located in the Biopharmaceutical Valley of Nanjing Jiangbei New District. Driven by independent innovative technologies, Jianda Biopharma focuses on the development and industrialization of new human vaccines and biopharmaceutical products such as tumor treatment. Since its establishment, the company has devoted itself to research and development and established a DC-targeted VLP vaccine technology platform and a circular mRNA vaccine technology platform with independent intellectual property rights. A series of innovative products based on platform technologies are in the POC, pilot production and pre-IND stages. In 2021, the company completed its angel round of financing, with Shenzhen Songshan Capital and Dongguan Juying Capital investing 33 million yuan, pushing multiple of the company's products from R&D to pre-IND. The company focuses on the field of life and health, introduces company teams, insists on pioneering and innovation, deploys multiple product pipelines, and strives to bring new vaccines developed to the market to benefit human life and health.

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company driven by self-developed technologies. We are dedicated to the R&D, production and commercialization of innovative vaccines, leveraging our core technology platforms (novel adjuvant, protein engineering, immunological evaluation). With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios consisting of ten-odd differentiated vaccines, covering cervical cancer, shingles, COVID-19, TB and other high-burden diseases. Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial and has a leading research and development progress. Apart from that, ReCOV, a recombinant COVID-19 vaccine, has been recognized as one of the most competitive next-generation COVID-19 vaccines in the world. Recbio has a clear commercialization strategy aiming to penetrate the diversified global vaccine market.

科兴制药是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业，专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发，并围绕上述治疗领域拥有一定中药及化学药技术沉淀。 科兴制药主要产品包括重组蛋白药物"重组人促红素"、"重组人干扰素α1b"、"重组人粒细胞刺激因子"，微生态制剂药物"酪酸梭菌二联活菌"。公司主要产品已沉淀一定行业优势地位和市场影响力，近年来依托政策支持和营销渠道深耕，保持稳定增长。

Likang Life Sciences is an innovative enterprise dedicated to development of immune cell therapy, with tumor-specific neoantigen as the target. It aims to provide personalized diagnosis and treatment services for cancer patients with the most cutting-edge precise detection and treatment methods. By now, the company has established close cooperative relationship with Chinese PLA General Hospital (301 Hospital), Beijing Cancer Hospital, and Cancer Hospital Chinese Academy of Medical Sciences, and is preparing several clinical trials. The company's goal is to establish a top cancer treatment center with advanced concepts, leading technologies and standardized services, and lead cancer treatment into a new era of personalized tumor immunotherapy.

The company makes vaccines and is currently working on a Shingles vaccine.

NanoRibo, founded in May 2021, is a biopharmaceutical technology company specializing in mRNA-related research and development of innovative vaccines and drugs. Our founding team, with over 20 years of expertise in virology and vaccine research, has played pivotal roles in esteemed research institutions and multinational corporations (MNCs) worldwide with extensive involvement in mRNA research and development, granting us genuine mastery of the technical know-how in the mRNA field. NanoRibo boasts a solid foundation in pathogenic biology, immunology, molecular biology, and bioinformatics. We are dedicated to fostering original innovation and have created a cutting-edge platform for researching and developing mRNA vaccines and drugs. Our mission at NanoRibo is to pioneer the biopharmaceutical industry, excelling in innovation and thriving in the global market. We possess proprietary non-coding region sequences, codon optimization algorithms, antigen design and optimization methods based on AI/Deep Learning, circRNA purification processes, LNP lyophilization techniques, and other innovative solutions to industry challenges. Utilizing the advantages of our mRNA technology platform, we focus on addressing the pressing need for enhancing existing technologies or filling gaps in the market for vaccines and other immunotherapies.

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

NOVOPROTEIN SCIENTIFIC , the mRNA reagent materials and recombinant proteins supplier from China. Novoprotein provides a one-stop solution of mRNA raw materials and services to support mRNA vaccines research and development. Our products include restriction enzymes, T7 RNA Polymerase, RNase inhibitor, Pyrophosphatase, DNaseI, Nucleotides, Vaccinia Capping Enzyme, mRNA 2´-O-Methyltransferase, Poly(A) Polymerase, RNase R, etc. The manufacturing processes are strictly controlled to ensure the products are animal-free and ampicillin-free. We guarantee the manufacturing and quality control comply with GMP regulation for tracking each step of the manufacturing process, including raw material sourcing. Novoprotein has developed more than ten thousand of recombinant proteins, like cytokines in cell therapy and organoid culture. We have researched and developed 7 technology platforms and 23 core technologies, including protein design and modification, protein production and quality control, protein application and evaluation. Novoprotein provides biomedical Industry customers with services from product development to technological innovation based on a comprehensive technology system and in-house innovative raw materials. James Pan - International Business Development email address: panyanzhi@novoprotein.com.cn

Oculgen Biopharma (Shen Zhen Oculgen BioMedical Technology Co. ,Ltd.) has a portfolio of the latest and best breakthrough ophthalmic treatment technology products covering the stages from early new drug target discovery, independent innovation, and commercialization. It hopes to address unmet clinical needs in the field of ophthalmic diseases and benefit global ophthalmic patients by providing innovative drugs in China, Asia, and around the world.

About Us As a contract research organization (CRO) in pharmaceutical R&D and clinical studies, Panacro Pharmaceutical Technology Co., Ltd. is committed to providing overall solutions for clinical studies & IND and NDA of chemical & biological drugs and vaccines. Since its establishment in 2004, Panacro has provided professional technical services to hundreds of customers at home and abroad in 20+ major therapeutic fields. In addition, it established offices in 20 major provinces or cities in China. With complete and detailed standard operating procedures (SOPs), and a professional team operating in accordance with international standards (ICH-GCP), it has built close cooperation with 80% study sites in China. Panacro focuses on providing customers with quality and efficient professional services, in order to shorten the product marketing cycle, and facilitate the product marketization. By virtue of a professional technical team and an operation team operating in strict accordance with relevant standards, as well as professional and efficient quality service, we provide customers with highly customized solutions in a rigorous and pragmatic way based on the principle of sincere cooperation and honest operation.

RongCan Biotech focuses on the development and industrialization of nucleic acid-based therapeutics, striving to become a whole-industry-chain company.

Tongji University is a comprehensive university located in Shanghai.

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality vaccines. Headquartered in China's southwestern city Kunming in Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines. With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, producing efficacious, quality, innovative and affordable products to protect people from the world's deadliest diseases, Walvax's purpose is to help everyone live a healthy life.

Xiamen Unversity is a public university in China.